Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with r...
Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA
Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL ( Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA )
30 Jun 2020
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )
30 Jun 2020
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC
Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC ( Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
30 Jun 2020
Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patient...
Prof Carmelo Carlo-Stella - Humanitas Cancer Center, Milan, Italy
Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patients with R/R diffuse large B-cell lymphoma ( Prof Carmelo Carlo-Stella - Humanitas Cancer Center, Milan, Italy )
26 Jun 2020
Treating patients with multiple myeloma in the real world
Dr Ajai Chari and Prof Roman Hájek
Treating patients with multiple myeloma in the real world ( Dr Ajai Chari and Prof Roman Hájek )
26 Jun 2020
ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine...
Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy
ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL ( Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )
26 Jun 2020
KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma
Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain
KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma ( Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain )
26 Jun 2020
Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients w...
Dr Naval Daver - MD Anderson Cancer Center, Houston, USA
Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients with TP53-mutant AML ( Dr Naval Daver - MD Anderson Cancer Center, Houston, USA )
26 Jun 2020
IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma
Prof Philippe Moreau - University of Nantes, Nantes, France
IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma ( Prof Philippe Moreau - University of Nantes, Nantes, France )
25 Jun 2020
ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and dexame...
Prof Efstathios Kastritis - University of Athens, Athens, Greece
ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and dexamethasone in newly-diagnosed AL amyloidosis ( Prof Efstathios Kastritis - University of Athens, Athens, Greece )
25 Jun 2020
The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blina...
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blinatumomab ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jun 2020
BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymp...
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jun 2020